Methods for the Diagnosis and Treatment of Lung Cancer

• US 20100062443A1
• Filed: 08/20/2009
• Published: 03/11/2010
• Est. Priority Date: 03/31/1998
• Status: Active Grant

• Current Assignee: Johns Hopkins University, Esoterix Genetic Laboratories LLC (Laboratory Corporation Of America Holdings)
• Original Assignee: Johns Hopkins University, Genzyme Corporation (Sanofi )
• Inventors: Beaudry, Gary A., Madden, Stephen L., Bertlesen, Arthur H., Sidransky, David, Jen, Jin
• Granted Patent: US 7,846,667 B2
• Time in Patent Office: Days
• US Class Current: 435/6
• CPC Class Codes: A61P 35/00 Antineoplastic agents
• CPC Class Codes: C12Q 1/6886 for cancer immunoassay for cancer G01N33/574
• CPC Class Codes: C12Q 2600/136 Screening for pharmacological compounds

Abstract

The present invention provides methods for aiding in the diagnoses of the neoplastic condition of a lung cell and methods of screening for a potential therapeutic agent for the reversal of the neoplastic condition.

Claims

1. A method for detecting and diagnosing the neoplastic condition of a lung cell, comprising detecting the presence of an overexpressed b-myb proto-oncogene in a lung cell sample, wherein the overexpression is indicative of the neoplastic condition of the lung cell.

32. The method of claim 1 or 31, further comprising detecting the expression level of the PGP9.5 proto-oncogene, wherein the presence of overexpression of the PGP9.5 and b-myb proto-oncogenes identifies the patient as having lung cancer or the neoplastic condition of the lung cell.

33. The method of claim 1 or 31, wherein detecting the expression level of the b-myb proto-oncogene comprises detecting the quantity of mRNA transcribed from the b-myb proto-oncogene.

34. The method of claim 1 or 31, wherein detecting the expression level of the b-myb proto-oncogene comprises detecting the quantity of cDNA produced from the reverse transcription of the b-myb mRNA.

35. The method of claim 1 or 31, wherein detecting the expression level of the b-myb proto-oncogene comprises detecting the quantity of the polypeptide or protein encoded by the b-myb proto-oncogene.

36. The method of claim 1 or 31, wherein the lung cancer is non-small cell lung cancer.

37. The method of claim 1 or 31, wherein detecting the expression level of the b-myb proto-oncogene comprises probing the lung cell sample with a probe or primer comprising the sequence TGCTGCCCTG (SEQ. ID No. 1) or its complement.

2-30. -30. (canceled)

31. A method for identifying a patient having lung cancer, comprising detecting the expression level of the b-myb proto-oncogene in a lung cell sample isolated from the patient, wherein the presence of overexpression of the b-myb proto-oncogene identifies the patient as having lung cancer.